169MO Development and validation of a magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with breast cancer: A multicenter cohort study

Abstract

59; p inter-action¼0.53). pCR rates (ypT0 ypN0) are shown in the table.Conclusions: A high RANK expression was associated with significantly higher pCR rates (49.6% vs. 39.4%; p¼0.037). This effect was pronounced in pts with luminal BC. However, a clinical benefit of Dmab in relation to RANK expression could not be shown. Further explorative analyses are still ongoing.Clinical trial identification: NCT02682693.

Assessment of the axilla in women with early-stage breast cancer undergoing primary surgery: a review

“…Based on the available research evidence, an alternative to SNB can be developed based on clinical, radiological and genomic data. As completion axillary dissection is Wang [124] Shan [125] Wang [126] Yu [127] Yu [128] Chen [129] Song [130] Obeid [131] Li [132] Liu [133] Tan [134] Zhang [135] Han [107] Zhang [136] Mao [120] CESM no longer recommended for patients with less than two nodes involved with cancer, a non-invasive model to predict the number of involved nodes could be valuable in de-escalating axillary management. It is also likely that these models, even if they don't accurately predict nodal status in all cases, may accurately predict prognosis, will have the same value as that of the nodal status in prognostication, and hence can replace SNB in most patients with EBC.…”